Update on minimally invasive surgery and benign prostatic hyperplasia

doi:10.1016/j.ajur.2017.06.001

Asian Journal of Urology, 2018, 5 (1): 22-27 doi: 10.1016/j.ajur.2017.06.001

Review

Current Issue | Archive | Adv Search

Update on minimally invasive surgery and benign prostatic hyperplasia

S.J.Chung Amanda^a,H.Woo Henry^b

^a Eastern Virginia Medical School, Norfolk, VA, USA
^b Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW, Australia

Abstract
Related Citation (15)

Download:

HTML

PDF (246KB)
Export: BibTeX | EndNote (RIS)

Abstract

Transurethral resection of the prostate (TURP) became the gold standard surgical treatment for benign prostatic obstruction without undergoing randomized controlled trials against the predecessor standard in open suprapubic prostatectomy. TURP has historically been associated with significant morbidity and this has fuelled the development of minimally invasive surgical treatment options. Improvements in perioperative morbidity for TURP has been creating an ever increasing standard that must be met by any new technologies that are to be compared to this gold standard. Over recent years, there has been the emergence of novel minimally invasive treatments such as the prostatic urethral lift (PUL; UroLift System), convective WAter Vapor Energy (WAVE; Rezum System), Aquablation (AQUABEAM System), Histotripsy (Vortx Rx System) and temporary implantable nitinol device (TIND). Intraprostatic injections (NX-1207, PRX-302, botulinum toxin A, ethanol) have mostly been used with limited efficacy, but may be suitable for selected patients. This review evaluates these novel minimally invasive surgical options with special reference to the literature published in the past 5 years.

Key words： Prostatic hyperplasia Prostatic diseases Minimally invasive surgical procedures Injections Botulinum toxin A Ethanol Transurethral resection of prostate Lasers Prostatectomy

Received: 11 February 2017 Published: 07 March 2018

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	S.J.Chung Amanda
	H.Woo Henry

TRENDMD:

Cite this article:

S.J.Chung Amanda,H.Woo Henry. Update on minimally invasive surgery and benign prostatic hyperplasia[J]. Asian Journal of Urology, 2018, 5(1): 22-27.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2017.06.001 OR http://www.ajurology.com/EN/Y2018/V5/I1/22

[1]	van Rij S, Gilling P . Recent advances in treatment for benign prostatic hyperplasia. F1000Res 2015: 4. . eCollection, 2015.
[2]	Aoun F, Marcelis Q, Roumeguere T . Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Res Rep Urol, 2015;7: 125-36.
[3]	Sivarajan G, Borofsky MS, Shah O, Lingeman JE, Lepor H . The role of minimally invasive surgical techniques in the management of large-gland benign prostatic hypertrophy. Rev Urol, 2015;17: 140-9.
[4]	Roberts WW . New technologies in benign prostatic hyperplasia management. Curr Opin Urol , 2016;26: 254-8.
[5]	Rukstalis DB . Prostatic urethral lift: a novel approach for managing symptomatic BPH in the aging man. Can J Urol, 2015; 22(Suppl. 1): 67-74.
[6]	McNicholas TA . Benign prostatic hyperplasia and new treatment options d a critical appraisal of the UroLift system. Med Devices (Auckl) , 2016;9: 115-23.
[7]	Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL , et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol , 2015;22: 7772-82.
[8]	Bozkurt A, Karabakan M, Keskin E, Hirik E, Balci MB, Nuhoglu B . Prostatic urethral lift: a new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol Int , 2016;96: 202-6.
[9]	Perera M, Roberts MJ , Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol, 2015;67: 704-13.
[10]	Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D , et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 Study. Eur Urol, 2015;68: 643-52.
[11]	Nair SM, Pimentel MA, Gilling PJ . Evolving and investigational therapies for benign prostatic hyperplasia. Can J Urol , 2015; 22(Suppl. 1): 82-7.
[12]	Ray A, Morgan H, Wilkes A, Carter K, Carolan-Rees G . The Urolift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a NICE medical technology guidance. Appl Health Econ Health Policy, 2016;14: 515-26.
[13]	McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND , et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol, 2016;195: 1529-38.
[14]	Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L , et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology, 2015;86: 1042-7.
[15]	McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND , et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med, 2016;13: 924-33.
[16]	Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G , et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology, 2015;86: 122-7.
[17]	Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D . Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int, 2015;116: 278-87.
[18]	Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I , et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol, 2015;29: 63-9.
[19]	Gilling P, Reuther R, Kahokehr A, Fraundorfer M . Aquablation e image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int, 2016;117: 923-9.
[20]	Darnell SE, Hall TL, Tomlins SA, Cheng X, Ives KA, Roberts WW . Histotripsy of the prostate in a canine model: characterization of post-therapy inflammation and fibrosis. J Endourol, 2015;29: 810-5.
[21]	Kunit T, Lusuardi L . An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol, 2014;6: 67-70.
[22]	Ebbing J, Bachmann A . Anesthesia-free procedures for benign prostate obstruction: worth it? Curr Opin Urol , 2015;25: 32-9.
[23]	Hsu YC, Wang HJ , Chuang YC. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasiad a spotlight in reality. Toxins(Basel), 2016: 8.
[24]	Shim SR, Cho YJ, Shin IS, Kim JH . Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol, 2016; 48: 19-30.
[25]	Ding XD, Chen HX, Xiao HQ, Wang W, Ding ZG, Zhang GB , et al. Treatment of benign prostatic hyperplasia by ultrasoundguided botulinum toxin type A injection. Cell Biochem Biophys, 2015;73: 357-9.
[26]	Alam M, Zgheib J, Dalati MF , El Khoury F. Botulinum toxin A injection in the bladder neck: a promising treatment for urinary retention. Case Rep Urol, 2016; 2016: 6385276. https://doi.org/10.1155/2016/6385276. Update on minimally invasive surgery and BPH 27 doi: https://doi.org/10.1155/2016/6385276